L'intérêt à découvert pour MGO Global donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de MGO Global. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

MGO Global (NASDAQ:MGOL) Stock, Rapport sur les intérêts à découvert

MGO Global

MGO Global Inc has built a brand acceleration platform with a focus on the acquisition, optimization and monetization of consumer brands across multiple categories. Its mission is to provide customers with unmatched variety, quality and shopping experience. The Company has three reportable segments: 1) The Messi Store, which sells a range of products under The Messi Brand; 2) Stand Flagpoles, which sells a range of residential flagpoles and related products direct to consumers; and 3) Corporate, which generates no revenue, but reflects corporate expenses related primarily to being a public company.

MGO Global Inc

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $150 to $136.

News

Price Target

Analyst Ratings

ILMN

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $136

MSFT

NVDA

ORCL

OpenAI's Sam Altman At Paris AI Meeting To Reuters: When Asked To Comment About Musk's Offer To Buy OpenAI, Altman Said: "I Have Nothing To Say. I Mean, It's Ridiculous, The Company Is Not For Sale. It's Another One Of Musk's Tactics To Try To Mess With Us"

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Aware Of Trade Deficit, But Doesn't Affect Fed's Mandate Goals; Commit To Following The Data On Effects Of Tariffs, As We Did In 2018-19

Morgan Stanley analyst Chris Snyder maintains Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) with a Equal-Weight and raises the price target from $210 to $217.

Morgan Stanley Maintains Equal-Weight on Honeywell Intl, Raises Price Target to $217

WIIM

IBM shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $320.

On Monday, Germany-based Merck KGaA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), which has a market capitalization of $4.02 billion, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Merck Germany also <a target="_blank" href="https://www.emdgroup.com/ad-hoc/us/ad-hoc-NA-10Feb2025.pdf" rel="noreferrer noopener">confirmed</a> that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met.
Reuters was the first to <a target="_blank" href="https://www.benzinga.com/quote/SWTX" rel="noreferrer noopener">report the potential deal</a>.
SpringWorks Therapeutics&#8217; first commercial product, Ogsiveo (nirogacestat), is a twice-daily oral medication that&nbsp;is the&nbsp;first and only&nbsp;FDA-approved&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35974211/fda-approves-springworks-therapeutics-lead-therapy-as-first-for-subtype-of-soft-tissue-sarcomas" rel="noreferrer noopener">treatment for desmoid tumors.</a>
In January, rare diseases and cancer-focused SpringWorks Therapeutics reported preliminary fourth quarter and full-year 2024 U.S. net product revenue for Ogsiveo of $61.5 million and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940198/springworks-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-financial-results-a" rel="noreferrer noopener">$172.0 million, respectively</a>.
The company is scheduled to report Q4 earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43331898/springworks-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday" rel="noreferrer noopener">on 20 February</a>.
The company&#8217;s second potential commercial product, mirdametinib (NF1-PN), for adults and children with NF1-associated plexiform neurofibromas or NF1-PN, is under FDA review with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940198/springworks-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-financial-results-a" rel="noreferrer noopener">PDUFA of 28 February</a>.
As of 31 December 2024, total preliminary cash, cash equivalents, and marketable securities were $461.9 million. SpringWorks expects its cash position to fund operations through profitability, which the company anticipates achieving in the first half of 2026.
Citing JPMorgan analysts Reuters report added that Merck KGaA&#8217;s oncology business, making up about 25% of its healthcare sales in 2024, could benefit from acquiring SpringWorks.
The report mentions the deal would complement Merck&#8217;s existing portfolio and create growth opportunities. Additionally, SpringWorks&#8217; products have the potential to help counter revenue losses from expiring drug patents and increased competition.
Price Action: SWTX stock is down 3.91% at $51.89 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/02/43624237/sp-globals-ratings-power-q4-surge-capital-returns-sweeten-the-deal" target="_blank" rel="noreferrer noopener">S&amp;P Global&#8217;s Ratings Power Q4 Surge, Capital Returns Sweeten The Deal</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

MKGAF

MKKGY

SWTX

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Benchmark analyst Mark Zgutowicz maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Buy and raises the price target from $180 to $220.

DASH

Benchmark Maintains Buy on DoorDash, Raises Price Target to $220

Fed Chair Powell Says Manufacturing Is Smaller Part Of Economy Than Before, Though Still Important; Healthy Manufacturing Is Important To Overall Economy

Morgan Stanley analyst Nigel Dally maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Equal-Weight and raises the price target from $123 to $125.

Morgan Stanley Maintains Equal-Weight on Globe Life, Raises Price Target to $125

Fed Chair Powell Says We Want To Run A Strong Labor Market, One Of The Benefits Is That Black-white Employment Gap Comes Down

Benchmark analyst Mike Hickey maintains Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) with a Buy and raises the price target from $16 to $18.

GAMB

Benchmark Maintains Buy on Gambling.com Gr, Raises Price Target to $18

Morgan Stanley analyst Vincent Andrews maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Equal-Weight and lowers the price target from $90 to $74.

Morgan Stanley Maintains Equal-Weight on Bunge Global, Lowers Price Target to $74

Fed Chair Powell Says Fed Pursuing Mandate Is Single Best Thing Fed Can Do To Narrow Gaps By Race; Still Have Quite A Bit Of Equity Data On Our Website

GM CEO: We Think We Can Mitigate 30% To 50% Of Tariffs Without Deploying Capital

INTC

Intel shares are trading higher after reviewers praised its latest processor, the Core Ultra 9 275HX, as the "fastest chip yet".

<a href="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/" title="http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/">http://www.forbes.com/sites/johnkang/2025/02/11/meta-in-talks-to-buy-korean-ai-chip-startup-founded-by-samsung-engineer/</a>

Meta Is In Talks To Acquire South Korean AI Chip Startup Furiosaai

Guidance

CORRECTION: FIS Expects Q1 2025 Revenue Of $2.485B - $2.510B Vs. $2.57B Estimate, Adjusted EPS Of $1.17-$1.22 Vs. $1.28 Estimate

JMP Securities analyst Mitch Germain maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Market Outperform and lowers the price target from $35 to $32.

SAFE

JMP Securities Maintains Market Outperform on Safehold, Lowers Price Target to $32

Fed Chair Powell Says Don't Believe Musk Or Team Has Tried To Access Fed Systems; Commit To Letting Committee Know If So

Editor&#8217;s note: This story has been updated with additional details. 
Federal Reserve Chair Jerome Powell reiterated on Tuesday that policymakers are in no "hurry" to adjust interest rates, citing lingering inflation pressures despite significant progress toward the<a href="https://www.benzinga.com/news/econ-s"> Fed's 2% inflation goal.</a>
Speaking before the Senate Banking Committee in Washington, Powell described the economic landscape as one where "the economy is strong overall." with a labor market that has cooled from its overheated state but remains resilient.
Over the past four months, payroll job gains averaged 189,000 per month, while the unemployment rate held steady at 4% in January. Powell indicated that "the labor market is not a source of significant inflationary pressures."
On inflation, Powell highlighted a notable decline over the past two years but stressed that "inflation remains somewhat elevated."
The latest Personal Consumption Expenditures price index showed a 2.6% year-over-year increase as of December, with core PCE rising 2.8%, excluding volatile food and energy costs. 
<h3 class="wp-block-heading">Powell Stresses Caution In Interest Rate Policy</h3>
Since September, the Federal Open Market Committee has lowered the policy rate by a full percentage point from its peak. 
Powell described this shift as "appropriate in light of the progress on inflation and the cooling in the labor market."
Despite these moves, Powell reiterated that "we do not need to be in a hurry to adjust our policy stance." 
He stated that reducing interest rates &#8220;too fast or too much&#8221; could derail progress on inflation, while moving too slowly or too little "could unduly weaken economic activity and employment."
Going forward, the Fed will continue to remain data dependent, before making further policy adjustments.
<h3 class="wp-block-heading">Powell Pushes Back Recession Concerns, Refrains From Tariff Judgement</h3>
During the Q&amp;A session, Powell pushed back against recession risks and reiterated the broader strength of the economy. 
Sen. John Kennedy (R-LA) questioned the Fed's influence over long-term bond yields, to which Powell responded, "We have some influence, but mostly not." 
The Fed Chair indicated that long-term rates are driven by future short-term rate expectations, inflation risks, and the budget deficit—factors beyond the Fed's direct control. 
When asked if a president could remove a Federal Reserve Board member, Powell said, "It's not allowed under the law."
Sen. Bill Hagerty (R-TN) asked Powell if the neutral rate — the point where interest rates neither boost nor slow the economy — has risen.
&#8220;The neutral rate will have risen meaningfully," Powell said.
The chairman highlighted that concerns over labor market weakness and inflation have faded. Powell said that many of his colleagues also believe the neutral rate has moved higher, a shift from its historically low pre-pandemic levels.
On trade policy, Sen. Jack Reed (D-RI) referenced Powell's 2018 statement that "countries that have remained open to trade, that have not erected barriers, including tariffs, have grown faster and achieved higher incomes." 
Powell stood by that view but refrained from commenting on specific trade policies, including President Donald Trump's tariffs on China, Canada, and Mexico. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43627524/economists-betting-markets-predict-benign-january-inflation-what-could-go-wrong-this-time">Economists, Betting Markets Predict Benign January Inflation: What Could Go Wrong This Time?</a></li>
</ul>

Econ #s

Fed's Powell Reiterates No 'Hurry' To Cut Interest Rates As Inflation Remains 'Somewhat Elevated' (UPDATED)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) just reported results for the second quarter of 2024.<ul><li>MGO Global reported earnings per share of -$1.33.</li><li>The company reported revenue of $1.43 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mgol-stock-earnings-mgo-global-for-q2-of-2024/">MGOL Stock Earnings: MGO Global Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MGOL Stock Earnings: MGO Global Reported Results for Q2 2024

MGO Global reports GAAP EPS of -$1.35, revenue of $1.43M

MGO Global files to sell common stock and warrants

Reports Q3 revenue $565,400 vs. $1.1M last year. Maximiliano Ojeda, Co-Founder, Chairman and CEO of MGO, stated, "As we continue to advance the com...

MGO Global reports Q3 EPS (54c) vs. ($1.43) last year

MGO Global&nbsp; GAAP EPS of -$1.90, revenue of $2.66M

MGO Global (MGOL) announced the pricing of its public offering of 6,315,000 units at a public offering price of $0.95 per unit. Each unit consists ...

MGO Global prices 6.3M shares at 95c in public offering

MGO Global rises 1%, closes $6M stock offering

MGO Global Inc. ( ($MGOL) ) has shared an update. MGO Global Inc. announced the successful pricing and closing of its public offering, raising $6 m...

MGO Global Inc. Closes $6 Million Public Offering

Conduit Pharmaceuticals, MGO Global Inc., and Cyclo Therapeutics are the 3&nbsp;Penny Stocks&nbsp;to watch on February 11, 2025, based on&nbsp;TipR...

3 Penny Stocks to Watch Now, 2/11/25

Turbo Energy (TURB) announced the appointment of Julian Groves to the Company's Board of Directors, which was approved by the Company's shareholder...

Comments

MGO Global

Intérêt court

MGO Global (NASDAQ:MGOL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL